http://www.oncologynurseadvisor.com/skin-cancer/topic/7532/ Articles tagged with Skin Cancer from ONA ONA Admin@haymarketmedia.com no Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma http://www.oncologynurseadvisor.com/asco-combo-antibody-therapy-effective-for-melanoma/article/293840/ Fri, 17 May 2013 19:00:00 GMT Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma ONA Older individuals with nonmelanoma skin cancer seem to have a significantly reduced risk of developing Alzheimer's disease, according to a Neurology study. http://www.oncologynurseadvisor.com/nonmelanoma-skin-cancer-tied-to-lower-alzheimers-risk/article/293637/ Fri, 17 May 2013 13:00:00 GMT Older individuals with nonmelanoma skin cancer seem to have a significantly reduced risk of developing Alzheimer's disease, according to a Neurology study. ONA White people who have types of skin cancer other than melanoma may be at increased risk of having other forms of cancer in the future, according to a new study. http://www.oncologynurseadvisor.com/skin-cancer-linked-to-future-risk-of-other-cancers/article/293436/ Wed, 15 May 2013 19:00:00 GMT White people who have types of skin cancer other than melanoma may be at increased risk of having other forms of cancer in the future, according to a new study. ONA A new study focused on the vexing problem of how best to handle skin cancers among frail, elderly patients. http://www.oncologynurseadvisor.com/frail-elderly-patients-may-not-benefit-from-surgery-for-nonfatal-skin-cancers/article/292195/ Mon, 06 May 2013 23:30:00 GMT A new study focused on the vexing problem of how best to handle skin cancers among frail, elderly patients. ONA The FDA has designated Merck's lambrolizumab (MK-3475) as Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor. http://www.oncologynurseadvisor.com/lambrolizumab-given-breakthrough-therapy-designation-for-advanced-melanoma/article/292056/ Mon, 06 May 2013 11:00:00 GMT The FDA has designated Merck's lambrolizumab (MK-3475) as Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor. ONA Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab. http://www.oncologynurseadvisor.com/ct-data-help-predict-survival-in-metastatic-melanoma/article/290202/ Tue, 30 Apr 2013 11:00:00 GMT Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab. ONA History of non-melanoma skin cancer associated with a greater risk of secondary cancers at other sites. http://www.oncologynurseadvisor.com/prior-skin-cancer-ups-risk-for-secondary-cancers/article/290725/ Fri, 26 Apr 2013 16:00:00 GMT History of non-melanoma skin cancer associated with a greater risk of secondary cancers at other sites. ONA The incidence of pediatric melanoma has increased by about 2% per year, and this incidence trend is influenced by gender, age, and stage at diagnosis, primary site, and UV-B exposure. http://www.oncologynurseadvisor.com/pediatric-melanomas-increasing-by-2-each-year/article/288964/ Tue, 16 Apr 2013 13:00:00 GMT The incidence of pediatric melanoma has increased by about 2% per year, and this incidence trend is influenced by gender, age, and stage at diagnosis, primary site, and UV-B exposure. ONA A new reconstruction technique uses cartilage from behind the ear and skin from the shoulder to repair the nose in one step after skin cancer. http://www.oncologynurseadvisor.com/new-reconstructive-procedure-repairs-nose-after-skin-cancer-in-just-one-step/article/287042/ Tue, 02 Apr 2013 13:00:00 GMT A new reconstruction technique uses cartilage from behind the ear and skin from the shoulder to repair the nose in one step after skin cancer. ONA Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response. http://www.oncologynurseadvisor.com/melanoma-uses-weak-immune-cells-to-its-advantage/article/284263/ Mon, 18 Mar 2013 11:00:00 GMT Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response. ONA